Highlights
APG-2449 acts as both a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) and a focal adhesion kinase (FAK) inhibitor, addressing resistance pathways that often bypass traditional TKI therapy.
In patients resistant to second-generation ALK inhibitors, APG-2449 achieved an objective response rate (ORR) of 45.5% and a median progression-free survival (mPFS) of 13.6 months.
